A Phase 1 interventional study of GT-02287 in Parkinson Disease, sponsored by Gain Therapeutics, Inc.. Recruiting at 7 sites in Australia. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by Gain Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Parkinson Disease with a site in Australia — 10 open to participants now, 12 under way, 3 of them phase 3. Parkinson Disease · Australia.
Among the 59 studies in Parkinson Disease with a site in Australia, this one is the 50th largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2025, is one of 8 in phase 1, reaches primary completion later than 1 of the 11 other live ones, and was the 53rd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →10 of the 59 studies in Parkinson Disease with a site in Australia are open now. Recruiting first, the newest first:
Serina Therapeutics · Sites in Australia, United States, Taiwan
Ages 40–80
Hoffmann-La Roche · Sites in Australia, United States, Austria and 14 more countries
Ages 50–85
The University of New South Wales · Sites in Australia
Ages 18+
BlueRock Therapeutics · Sites in Australia, United States, Canada
Ages 45–75
Longevity Biotech Australia Pty Ltd (subsidiary) · Sites in Australia
Ages 30–89 · Healthy volunteers
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 12 · Phase 3 28 · Phase 4 2
First in 2002; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 132 across the 54 interventional studies, 234 across the 5 observational. Of the 43 that completed or were terminated, 20 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 59 have an industry lead sponsor. The 10 most frequent:
Gain Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Gain Therapeutics, Inc. has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Parkinson Disease with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07422675Serina TherapeuticsSAD Study in Patients With Parkinson's Disease and Motor Fluctuations | 2027-01-31 |
| NCT06466525Longevity Biotech Australia Pty Ltd (subsidiary)A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease. | 2027-02 |
| NCT07630545Mission TherapeuticsA Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients. | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 59 studies in Parkinson Disease with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are:
Participants will:
This Phase 1b, 3-month, multicenter, open-label study of GT-02287 in participants with Parkinson's Disease with or without GBA1 mutations. The primary objective of the study is to evaluate the safety and tolerability of GT-02287. The study will also investigate pharmacokinetics (PK) and explore pharmacodynamic parameters in blood and CSF and effect of GT-02287 on scores from selected clinical scales. Approximately 20 participants will be enrolled to result in approximately 15 evaluable participants.
All participants will receive an oral dose of GT-02287 of 13.5 mg/kg/day (plus/minus 2 mg/kg/day) once a day for 90 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: GT-02287
Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent
Incidence, nature, relationship to investigational product (IP), and severity of adverse events (AEs)
Time frame: From first dose to Day 105
Incidence of clinically significant findings for clinical laboratory evaluations, physical and neurological examinations, body weight , vital signs measurements, 12-lead o 12-lead electrocardiograms (ECGs), Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: From first dose to Day 105
Maximum Plasma Concentration [Cmax]
Pharmacokinetics
Time frame: Day 1 and Day 90
Area under the curve [AUC]
Pharmacokinetics
Time frame: Day 1 and Day 90
Time to reach Cmax [Tmax]
Pharmacokinetics
Time frame: Day 1 and Day 90
Elimination half life [T1/2]
Pharmacokinetics
Time frame: Day 90- Day 93
Apparent Clearance (CL/F)
Pharmacokinetics
Time frame: Day 90- Day 93
Apparent Volume of Distribution (Vz/F)
Pharmacokinetics
Time frame: Day1 and Day 90- Day 93
Gcase activity (µmol/L/h) measurement in dried blood spots (DBS)
Pharmacodynamics (Exploratory outcome): mean change from baseline in Gcase activity in DBS
Time frame: From first dose to Day 90
Concentration of sphingolipids in cerebrospinal fluid (CSF )
Pharmacodynamics (Exploratory outcome): mean change from baseline in sphingolipids in CSF
Time frame: From first dose to Day 90
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Nov 2025, 9 months after the start.
Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 9 months is close to that.
Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gain Therapeutics, Inc.